Atypical antipsychotics: Sedation versus efficacy

Journal of Clinical Psychiatry

Volumn 69, Issue SUPPL. 1, 2008, Pages 18-31

  Kane, John M ^a,b   Sharif, Zafar A ^c  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; HISTAMINE H1 RECEPTOR; HYPNOTIC AGENT; MUSCARINIC RECEPTOR; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; HYPNOTIC SEDATIVE AGENT; NEUROLEPTIC AGENT;

BIPOLAR DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERSOMNIA; INSOMNIA; MOOD DISORDER; ORTHOSTATIC HYPERTENSION; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SLEEP WAKING CYCLE; SOMNOLENCE; THERAPY; WEIGHT GAIN; ADULT; ARTICLE; BLOOD; BRAIN; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG EFFECT; HALF LIFE TIME; MALE; POLYSOMNOGRAPHY; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; RISK ASSESSMENT; SLEEP STAGE;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; BRAIN; DISORDERS OF EXCESSIVE SOMNOLENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HALF-LIFE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; POLYSOMNOGRAPHY; RISK ASSESSMENT; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SLEEP INITIATION AND MAINTENANCE DISORDERS; SLEEP STAGES;

EID: 45749147916     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. American Academy of Sleep Medicine. International Classification of Sleep Disorders, Revised: Diagnostic and Coding Manual. Chicago, Ill: American Academy of Sleep Medicine; 2001. Available at: http://www.absm.org/PDF/ICSD.pdf. Accessed June 27, 2007
2. Costa e Silva JA. Sleep disorders in psychiatry. Metabolism 2006;55(suppl 2):S40-S44
3. Monti J, Monti D. Sleep disturbance in schizophrenia. Int Rev Psychiatry 2005;17:247-253
4. Benson K. Sleep in schizophrenia: impairments, correlates, and treatment. Psychiatr Clin North Am 2006;29:1033-1045
5. Chesson A Jr, Hartse K, Anderson WM, et al, for the Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for the evaluation of chronic insomnia: an American Academy of Sleep Medicine report. Sleep 2000;23:237-241
6. Hofstetter J, Lysaker P, Mayeda A. Quality of sleep in patients with schizophrenia is associated with quality of life and coping. BMC Psychiatry 2005;5:13 Available at: http://www.biomedcentral.com/1471-244X/5/13. Accessed Aug 28, 2007
7. Monti J, Monti D. Sleep in schizophrenia patients and the effects of antipsychotic drugs. Sleep Med Rev 2004;8:133-148
8. Bauer M, Grof P, Rasgon N, et al. Temporal relationship between sleep and mood in patients with bipolar disorder. Bipolar Disord 2006;8:160-167
9. Keshavan MS, Reynolds CF, Miewald MJ, et al. Delta sleep deficits in schizophrenia: evidence from automated analyses of sleep data. Arch Gen Psychiatry 1998;55:443-448
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
11. Barbini B, Bertelli S, Colombo C, et al. Sleep loss, a possible factor in augmenting manic episode. Psychiatry Res 1996;65:121-125
12. Demet E, Chicz-Demet A, Fallon J, et al. Sleep deprivation in depressive illness and Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 1999;23:753-784
13. Larsen J, Lindberg M, Skovgaard B. Sleep deprivation as treatment for endogenous depression. Acta Psychiatr Scand 1976;54:167-173
14. Hoyt BD. Sleep in patients with neurologic and psychiatric disorders. Prim Care 2005;32:535-548
15. Buysse DJ, Reynolds CF 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213
16. Bastien C, Vallieres A, Morin C. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2001;2:297-307
17. Levine D, Kripke D, Kaplan R, et al. Reliability and validity of the Women's Health Initiative Insomnia Rating Scale. Psychol Assess 2003;15:137-148
18. Collaborative Working Group on Clinical Trial Evaluations. Adverse effects of the atypical antipsychotics. J Clin Psychiatry 1998;59(suppl 12):17-22
19. Wetterling T. Bodyweight gain with atypical antipsychotics: a comparative review. Drug Saf 2001;24:59-79
20. Abilify [package insert]. Tokyo, Japan: Otsuka America Pharmaceutical, Inc; 2006. Available at: http://www.otsuka.com/documents/AbilifyFullPI.pdf. Accessed June 6, 2007
21. Zyprexa [package insert]. Indianapolis, Ind: Eli Lilly and Company; 2006. Available at: http://pi.lilly.com/us/zyprexa-pi.pdf. Accessed April 17, 2007
22. Seroquel [package insert]. Wilmington, Del: AstraZeneca Pharmaceuticals; 2006. Available at: http://www.astrazeneca-us.com/pi/seroquel.pdf. Accessed Jan 31, 2007
23. Risperdal [package insert]. Titusville, NJ: Janssen, L.P.; 2007. Available at: http://www.janssen.com/active/janus/en_US/assets/common/company/ pi/risperdal.pdf. Accessed June 25, 2007
24. Clozaril [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2005. Available at: http://www.pharma.us.novartis.com/product/pi/ pdf/Clozaril.pdf. Accessed June 25, 2007
25. Ramaekers J. Behavioural toxicity of medicinal drugs: practical consequences, incidence, management and avoidance. Drug Saf 1998;18:189-208
26. Geodon [package insert]. New York, NY: Pfizer, Inc; 2007. Available at: http://www.pfizer.com/pfizer/download/uspi_geodon.pdf. Accessed June 6, 2007
27. Hien le TT, Cumming RG, Cameron ID, et al. Atypical antipsychotic medications and risk of falls in residents of aged care facilities. J Am Geriatr Soc 2005;53:1290-1295
28. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28:519-526
29. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999;60(suppl 10):5-14
30. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005;172:1703-1711
31. Howard ME, Desai AV, Grunstein RR, et al. Sleepiness, sleep-disordered breathing, and accident risk factors in commercial vehicle drivers. Am J Respir Crit Care Med 2004;170:1014-1021
32. Nicholson AN, Pascoe PA, Turner C, et al. Sedation and histamine H1-receptor antagonism studies in man with the enantiomers of chlorpheniramine and dimethindene. Br J Pharmacol 1991;104:270-276
33. Monti JM. Pharmacology of the histaminergic system. In: Kales A, ed. Pharmacology of Sleep. The Handbook of Experimental Pharmacology, vol 116. New York, NY: Springer; 1995
34. Monti JM. Involvement of histamine in the control of the waking state. Life Sci 1993;53:1331-1338
35. Onodera K, Yamatodani A, Watanabe T, et al. Neuropharmacology of the histaminergic neuron system in the brain and its relationship with behavioral disorders. Prog Neurobiol 1994;42:685-702
36. Tuomisto L. Involvement of histamine in circadian and other rhythms. In: Watanabe T, Wada H, eds. Histaminergic Neurons: Morphology and Function. Boca Raton, Fla: CRC Press, Inc.; 1991:283-286
37. Inoue I, Yanai K, Kitamura D, et al. Impaired locomotor activity and exploratory behavior in mice lacking histamine H1 receptors. Proc Natl Acad Sci U S A 1996;93:13316-13320
38. Buckley PF. Receptor-binding profiles of antipscyhotics: clinical strategies when switching between agents. J Clin Psychiatry 2007;68(suppl 6):5-9
39. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
40. McEvoy J. Assessment of the acutely agitated patient with psychosis. Presented at the 158th annual meeting of the American Psychiatric Association; May 21-26, 2005; Atlanta, Ga
41. Yildiz A, Sachs GS, Turgay A. Pharmacological management of agitation in emergency settings. Emerg Med J 2003;20:339-346
42. Expert Consensus Guideline Series: Treatment of Schizophrenia 1999. J Clin Psychiatry 1999;60(suppl 11):1-80
43. Sullivan G, Bienroth M, Jones M, et al. Practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a UK multidisciplinary panel. Curr Med Res Opin 2007;23:1733-1744
44. Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry 2004;6(suppl 2):3-7
45. Carlson PJ, Merlock MC, Suppes T. Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation. Bipolar Disord 2004;6:416-420